Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
A Randomized, Blind, and Positive Control Design to Evaluate the Immunization Efficacy of 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-26 Years
Sponsor: Beijing Kantorico Statistical Technology Co., Ltd.
This PHASE2 trial investigates HPV Infection and HPV-Related Cervical Carcinoma and is currently completed. Beijing Kantorico Statistical Technology Co., Ltd. leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Dec 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Dec 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE2
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Kantorico Statistical Technology Co., Ltd.
- Chengdu Institute of Biological Products Co.,Ltd.
- Guangxi Center for Disease Control and Prevention
- National Vaccine and Serum Institute, China
- Simoon Record Pharma Information Consulting Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .